These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 23587852)

  • 1. Cocoon formation in patients with midgut neuroendocrine tumors: a rare and unrecognized final pathway.
    Wang YZ; King H; Diebold A
    Pancreas; 2013 Aug; 42(6):944-8. PubMed ID: 23587852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Re-evaluation of cases with gastroenteropancreatic neuroendocrine tumors between 2004 and 2012 according to the 2010 criteria.
    Ozkara S; Aker F; Yesil A; Senates E; Canbey C; Yitik A; Gonen C
    Hepatogastroenterology; 2013 Oct; 60(127):1665-72. PubMed ID: 24627925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of primary tumors in patients presenting with metastatic gastroenteropancreatic neuroendocrine tumors.
    Keck KJ; Maxwell JE; Menda Y; Bellizzi A; Dillon J; O'Dorisio TM; Howe JR
    Surgery; 2017 Jan; 161(1):272-279. PubMed ID: 27863780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma chromogranin A levels predict survival and tumor response in patients with advanced gastroenteropancreatic neuroendocrine tumors.
    Chou WC; Chen JS; Hung YS; Hsu JT; Chen TC; Sun CF; Lu CH; Hwang TL
    Anticancer Res; 2014 Oct; 34(10):5661-9. PubMed ID: 25275071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver transplantation for gastroenteropancreatic neuroendocrine cancers: Defining selection criteria to improve survival.
    van Vilsteren FG; Baskin-Bey ES; Nagorney DM; Sanderson SO; Kremers WK; Rosen CB; Gores GJ; Hobday TJ
    Liver Transpl; 2006 Mar; 12(3):448-56. PubMed ID: 16498656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate.
    Kamp K; Gumz B; Feelders RA; Kwekkeboom DJ; Kaltsas G; Costa FP; de Herder WW
    Endocr Relat Cancer; 2013 Dec; 20(6):825-31. PubMed ID: 24036133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Symptomatic presentation as a predictor of recurrence in gastroenteropancreatic neuroendocrine tumors: A single institution experience over 15 years.
    Baptiste GG; Postlewait LM; Ethun CG; Le N; McInnis MR; Russell MC; Winer JH; Kooby DA; Staley CA; Maithel SK; Cardona K
    J Surg Oncol; 2016 Aug; 114(2):163-9. PubMed ID: 27157897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic and therapeutic role of endoscopy in gastroenteropancreatic neuroendocrine neoplasms.
    Attili F; Capurso G; Vanella G; Fuccio L; Delle Fave G; Costamagna G; Larghi A
    Dig Liver Dis; 2014 Jan; 46(1):9-17. PubMed ID: 23731843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resection of primary tumor may prolong survival in metastatic gastroenteropancreatic neuroendocrine tumors.
    Tierney JF; Chivukula SV; Wang X; Pappas SG; Schadde E; Hertl M; Poirier J; Keutgen XM
    Surgery; 2019 Mar; 165(3):644-651. PubMed ID: 30366604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased Grade in Neuroendocrine Tumor Metastases Negatively Impacts Survival.
    Keck KJ; Choi A; Maxwell JE; Li G; O'Dorisio TM; Breheny P; Bellizzi AM; Howe JR
    Ann Surg Oncol; 2017 Aug; 24(8):2206-2212. PubMed ID: 28560597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The importance of clinical information in patients with gastroenteropancreatic neuroendocrine tumor.
    Kudo A; Akashi T; Kumagai J; Ban D; Inokuchi M; Kojima K; Kawano T; Tanaka S; Arii S
    Hepatogastroenterology; 2012; 59(120):2450-3. PubMed ID: 22584507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasms.
    Pommergaard HC; Nielsen K; Sorbye H; Federspiel B; Tabaksblat EM; Vestermark LW; Janson ET; Hansen CP; Ladekarl M; Garresori H; Hjortland GO; Sundlöv A; Galleberg R; Knigge P; Kjaer A; Langer SW; Knigge U
    J Neuroendocrinol; 2021 May; 33(5):e12967. PubMed ID: 33769624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour grade and primary site predict patterns of recurrence and survival in patients with resected gastroenteropancreatic neuroendocrine tumors.
    Watanabe A; Yip L; Hamilton TD; Loree JM; Stuart HC
    Am J Surg; 2021 Jun; 221(6):1141-1149. PubMed ID: 33795127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surgical management of neuroendocrine tumors.
    Tamburrino D; Spoletini G; Partelli S; Muffatti F; Adamenko O; Crippa S; Falconi M
    Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):93-102. PubMed ID: 26971846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival.
    Lee HS; Chen M; Kim JH; Kim WH; Ahn S; Maeng K; Allegra CJ; Kaye FJ; Hochwald SN; Zajac-Kaye M
    Int J Cancer; 2014 Jul; 135(1):128-37. PubMed ID: 24347111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GEP-NETS update: a review on surgery of gastro-entero-pancreatic neuroendocrine tumors.
    Partelli S; Maurizi A; Tamburrino D; Baldoni A; Polenta V; Crippa S; Falconi M
    Eur J Endocrinol; 2014 Oct; 171(4):R153-62. PubMed ID: 24920289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Threshold for Circulating Tumor Cells in Patients With Pancreatic and Midgut Neuroendocrine Tumors.
    Mandair D; Khan MS; Lopes A; Furtado O'Mahony L; Ensell L; Lowe H; Hartley JA; Toumpanakis C; Caplin M; Meyer T
    J Clin Endocrinol Metab; 2021 Mar; 106(3):872-882. PubMed ID: 33180939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs).
    Scott AT; Breheny PJ; Keck KJ; Bellizzi AM; Dillon JS; O'Dorisio TM; Howe JR
    Surgery; 2019 Jan; 165(1):166-175. PubMed ID: 30343949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection.
    Lv Y; Han X; Xu XF; Ji Y; Zhou YH; Sun HC; Zhou J; Fan J; Lou WH; Huang C
    BMC Cancer; 2019 Apr; 19(1):335. PubMed ID: 30961559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Surgical treatments for gastroenteropancreatic neuroendocrine tumor (GEP-NET)].
    Aoki T; Kokudo N
    Nihon Shokakibyo Gakkai Zasshi; 2014 Dec; 111(12):2272-9. PubMed ID: 25482902
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.